Tell us about your product, market, and timeline — our specialists will design a testing programme that fits.
Our scientific team will help you identify the right tests, methods, and accreditations for your product or sample.
The Gurugram (Manesar) Pharmaceutical Testing Laboratory at IMT Manesar provides USFDA-inspected and DCGI-approved pharmaceutical testing under NABL accreditation (ISO/IEC 17025:2017, Certificate TC-15532). DCGI approved since 1995, the Manesar facility supports stability, assay, dissolution, microbiological limits, particle size analysis (Malvern Mastersizer 3000), and Franz diffusion cell studies, with an integrated Clinical Research Division on the same site for BA / BE, PK / PD, HRIPT, and SPF in-vivo claim substantiation.
NABL Certificate: NABL TC-15532
Validity: Valid until February 2029
Phone: +91 74281 16100
Email: [email protected]
Six testing categories confirmed in the Manesar NABL TC-15532 scope (13 pharmaceutical entries plus 6 cosmetics and essential oils, and 2 radiological water parameters).
Quantitative assay of active pharmaceutical ingredients in finished dosage forms under NABL TC-15532 pharmaceutical scope (13 entries).
Real-time and accelerated stability studies under ICH-aligned conditions for finished pharmaceutical formulations.
USP apparatus dissolution and disintegration testing for solid and semi-solid dosage forms under NABL-accredited conditions.
Total aerobic microbial count, total yeast and mould, and pathogen testing per USP and IP for non-sterile pharmaceutical products.
Physicochemical testing for cosmetics and essential oils (6 parameters confirmed in TC-15532 scope) at the same facility.
Alpha and Beta emitter analysis in water samples (2 parameters confirmed in TC-15532 scope) for regulatory and operational reporting.
Co-located CRD: The Manesar facility hosts a Clinical Research Division on the same site for BA / BE studies, bioanalytical testing, PK / PD studies, HRIPT, and SPF in-vivo claim substantiation per ISO 24444. Explore clinical research services at Manesar →
Six of the most-requested analytical parameters at the Manesar pharmaceutical testing lab.
Quantitative assay of active pharmaceutical ingredients by HPLC, UPLC, UV, and titrimetric methods against pharmacopoeial limits.
USP apparatus dissolution testing and profiling for solid and semi-solid dosage forms under NABL-accredited conditions.
Real-time and accelerated stability studies under ICH-aligned controlled temperature and humidity protocols.
Laser diffraction particle size distribution from 0.01 to 3500 µm — confirmed instrument capability at the Manesar facility.
In-vitro permeation and release studies with 7 stations and synthetic membranes — confirmed setup at the Manesar facility for topical and transdermal formulations.
TPC, yeast and mould, and pathogen testing per USP and IP for non-sterile pharmaceutical products.
Six reasons pharmaceutical companies across the Gurugram-NCR corridor and international markets choose the Manesar lab.
US FDA-inspected pharmaceutical testing lab. Reports accepted by US FDA, ANDA / NDA filers, US importers, and international regulatory bodies.
Drugs Controller General of India (DCGI) approval continuously since 1995, supporting CDSCO submissions and Indian pharmaceutical filings.
Ideal for pharmaceutical companies needing USFDA-inspected pharmaceutical QC reports, contract manufacturer due diligence, and US market submissions.
The Manesar facility houses a Clinical Research Division on the same site — BA / BE, bioanalytical, PK / PD, HRIPT, and SPF in-vivo studies available alongside analytical testing.
Strategically located inside IMT Manesar, serving the Gurugram-NCR pharmaceutical manufacturing corridor with local sample logistics.
NABL TC-15532, Atomic Energy Regulatory Board (AERB) recognition for radiological water, and ISO 9001:2015 quality management — a complete pharmaceutical quality stack.
Four steps from initial enquiry to digital report. Standard TAT 5 to 7 working days. Express testing available.
Call your single point of contact at +91 74281 16100 to confirm the test scope, applicable pharmacopoeial standard, and sample submission details.
Drop the sample at the IMT Manesar address or send by pre-approved courier. Each sample is bar coded on receipt and registered in YLIMS.
Testing is conducted under NABL-accredited conditions (TC-15532) and USFDA-inspected protocols with in-process QA checks against the applicable standard.
The digital report is issued and accessible via YLIMS. Standard TAT 5 to 7 working days. Express testing available for time-critical batches.
Six credentials held at the Manesar facility supporting pharmaceutical testing.
ISO/IEC 17025:2017, Valid Feb 2029
US FDA inspected pharmaceutical testing facility
Drugs Controller General of India approved since 1995
Quality management system certified
Atomic Energy Regulatory Board recognised
Pharmaceutical drug testing licence
See the full national pharmaceutical testing scope, the co-located Clinical Research Division services, or return to the Manesar lab hub.
National pharmaceutical testing service page with the complete catalogue of methods, parameters, and supported pharmacopoeias.
Go to national service page →Co-located Clinical Research Division supporting BA / BE, bioanalytical, PK / PD, HRIPT, and SPF in-vivo claim substantiation studies.
Clinical trial enquiries →Manesar lab overview covering pharmaceutical, cosmetics, essential oils, radiological water, and Clinical Research Division scope.
Back to Manesar lab hub →NABL TC-15532 accredited pharmaceutical testing with USFDA Inspected and DCGI approved (since 1995) protocols at IMT Manesar. Standard TAT 5 to 7 working days. Express options available.
Download a practical testing guide tailored to your industry — checklists, parameters, and regulatory tips in one place.
Download Guide Request a Quote InsteadNo thanks, I'll keep browsing